Compare CORT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | TECH |
|---|---|---|
| Founded | 1998 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.4B |
| IPO Year | 2001 | 1995 |
| Metric | CORT | TECH |
|---|---|---|
| Price | $121.38 | $72.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | ★ $141.00 | $70.50 |
| AVG Volume (30 Days) | 872.9K | ★ 3.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | N/A | ★ 152.17 |
| EPS | 0.09 | ★ 1.16 |
| Revenue | $761,407,000.00 | ★ $1,215,039,000.00 |
| Revenue This Year | $50.53 | $4.35 |
| Revenue Next Year | $48.75 | $10.04 |
| P/E Ratio | $1,317.11 | ★ $62.46 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $43.20 |
| 52 Week High | $126.38 | $72.69 |
| Indicator | CORT | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 56.12 |
| Support Level | $108.33 | $72.36 |
| Resistance Level | $123.01 | $72.63 |
| Average True Range (ATR) | 5.11 | 0.15 |
| MACD | 0.39 | -0.04 |
| Stochastic Oscillator | 83.38 | 42.12 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.